Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)
Do not take Lantus® if you are allergic to insulin or any of the inactive ingredients
in Lantus®.
You must test your blood sugar levels while using insulin, such as Lantus®.
Do not make any changes to your dose or type of insulin without talking to your
healthcare provider. Any change of insulin should be made cautiously and only under
medical supervision.
Do NOT dilute or mix Lantus® with any other insulin or solution. It will
not work as intended and you may lose blood sugar control, which could be serious.
Lantus® must only be used if the solution is clear and colorless with no particles
visible. Do not share needles, insulin pens or syringes with others.
The most common side effect of insulin, including Lantus®, is low blood sugar
(hypoglycemia), which may be serious. Some people may experience symptoms
such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia
may be serious and life threatening. It may cause harm to your heart or brain. Other
possible side effects may include injection site reactions, including changes in
fat tissue at the injection site, and allergic reactions, including itching and
rash. In rare cases, some allergic reactions may be life threatening.
Tell your doctor about other medicines and supplements you are taking because they
can change the way insulin works. Before starting Lantus®, tell your doctor
about all your medical conditions including if you have liver or kidney problems,
are pregnant or planning to become pregnant, or are breast-feeding or planning to
breast-feed.
Indications and Usage for Lantus®
Prescription Lantus® is a long-acting insulin used to treat adults with type
2 diabetes and adults and children (6 years and older) with type 1 diabetes for
the control of high blood sugar. It should be taken once a day at the same time
each day to lower blood glucose.
Do not use Lantus® to treat diabetic ketoacidosis.
Click
here for additional important information for Lantus®.
Important Safety Information for Apidra® (insulin glulisine [rDNA origin] injection)
Do not use Apidra® during a low blood sugar reaction (hypoglycemia) or if you
are allergic to any of the ingredients in Apidra®.
You must test your blood sugar levels while using insulin, such as Apidra®.
Do not make any changes to your dose or type of insulin without talking to your
healthcare provider. Any change of insulin should be made cautiously and only under
medical supervision. Apidra® must only be used if the solution is clear and
colorless with no particles visible. Do not share needles, insulin pens or syringes
with others.
Apidra®, when given by injection under the skin, should not be mixed with insulins
other than NPH. Do not mix Apidra® with any insulin when used in the pump or
for intravenous administration.
The most common side effect of insulin, including Apidra®, is low blood sugar
(hypoglycemia), which may be serious. Some people may experience symptoms
such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia
may be serious and life threatening. It may cause harm to your heart or brain. Other
possible side effects may include low blood potassium, injection site reactions,
such as changes in fat tissue at the injection site, and allergic reactions, such
as itching and rash. Less common, but potentially more serious or life-threatening,
is generalized allergy to insulin, including anaphylactic reactions.
Tell your doctor about other medicines and supplements you are taking because they
can change the way insulin works. Before starting Apidra®, tell your doctor
about all your medical conditions including if you have liver or kidney problems,
are pregnant or planning to become pregnant, or are breast-feeding or planning to
breast-feed.
Indications and Usage for Apidra®
Prescription Apidra® is a rapid-acting insulin for adults with type 2 diabetes or
adults and children (4 years and older) with type 1 diabetes to improve blood sugar
control. Apidra® given by subcutaneous injection is usually used with a longer-acting
insulin. When used as a mealtime insulin, Apidra® should be given within 15 minutes
before or within 20 minutes after starting a meal.
Click
here for additional important information for Apidra®.